O
ORIC icon

OrbiMed’s Oric Pharmaceuticals ORIC Stock Holding History

OrbiMed’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.1M Sell
2,693,929
-947,827
-26% -$10.8M 0.68% 44
2025
Q4 		$29.8M Hold
3,641,756
– – 0.61% 48
2025
Q3 		$43.7M Buy
3,641,756
+2,742,475
+305% +$28.9M 1.03% 33
2025
Q2 		$9.13M Buy
899,281
+199,281
+28% +$1.34M 0.23% 61
2025
Q1 		$3.91M Buy
+700,000
New +$6.12M 0.09% 83
2024
Q3 		– Sell
-287,100
Closed -$2.03M – 129
2024
Q2 		$2.03M Hold
287,100
– – 0.04% 105
2024
Q1 		$3.95M Sell
287,100
-235,868
-45% -$2.8M 0.07% 100
2023
Q4 		$4.81M Sell
522,968
-370,700
-41% -$2.68M 0.1% 90
2023
Q3 		$5.41M Sell
893,668
-274,800
-24% -$2.25M 0.11% 97
2023
Q2 		$9.07M Sell
1,168,468
-206,000
-15% -$1.17M 0.16% 92
2023
Q1 		$7.83M Sell
1,374,468
-233,100
-15% -$1.22M 0.15% 91
2022
Q4 		$9.47M Sell
1,607,568
-480,000
-23% -$1.62M 0.18% 77
2022
Q3 		$6.68K Hold
2,087,568
– – 0.12% 98
2022
Q2 		$9.35K Hold
2,087,568
– – 0.17% 93
2022
Q1 		$11.1M Sell
2,087,568
-250,006
-11% -$2.25M 0.18% 97
2021
Q4 		$34.4M Hold
2,337,574
– – 0.44% 62
2021
Q3 		$48.9M Hold
2,337,574
– – 0.54% 51
2021
Q2 		$41.4M Hold
2,337,574
– – 0.42% 65
2021
Q1 		$57.3M Sell
2,337,574
-584,393
-20% -$18.5M 0.54% 53
2020
Q4 		$98.9M Hold
2,921,967
– – 0.87% 33
2020
Q3 		$73.1M Hold
2,921,967
– – 0.92% 33
2020
Q2 		$98.6M Buy
+2,921,967
New +$93.3M 1.39% 23

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed's ORIC Position: Q1 2026 in Review

OrbiMed reduced its Oric Pharmaceuticals (ORIC) stake by 26% in Q1 2026, selling an estimated $10.8M and leaving 2,693,929 shares worth $34.1M. The position accounts for 0.68% of the portfolio, ranked #44.

OrbiMed first reported a position in ORIC in Q2 2020 and has held it in 22 quarters since. The position peaked at $98.9M in Q4 2020. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • OrbiMed held 2,693,929 shares of Oric Pharmaceuticals worth $34.1M as of Q1 2026.
  • OrbiMed sold 947,827 Oric Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
  • Oric Pharmaceuticals made up 0.68% of OrbiMed's portfolio in Q1 2026, its #44 holding.
  • OrbiMed first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • OrbiMed's Oric Pharmaceuticals position peaked at $98.9M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.